Ibrance

DRUG3 trials

Sponsors

University of Michigan Rogel Cancer Center, Hospital San Carlos, Madrid, Pfizer

Conditions

Advanced or Metastatic Breast CancerBreast CancerProstate Cancer

Phase 2

A Phase II Study of Androgen Deprivation Therapy With or Without Palbociclib in RB-Positive Metastatic Prostate Cancer

CompletedNCT02059213

University of Michigan Rogel Cancer CenterProstate Cancer

Start: 2014-06-30End: 2019-06-04Updated: 2020-09-16

Unknown Phase

Observational Analysis of Palbociclib Treatment in Patients With First Line Therapy for Locally Advanced and/or Metastatic Breast Cancer

CompletedNCT04874025

Hospital San Carlos, MadridBreast Cancer

Start: 2021-07-31End: 2022-06-08Updated: 2022-08-08

A Study to Understand the Patients Confirmed to Have Advanced or Metastatic Breast Cancer and Receiving Palbociclib Treatment Using a Real-world Database

CompletedNCT06962969

PfizerAdvanced or Metastatic Breast Cancer

Start: 2025-06-30End: 2025-10-23Updated: 2026-04-02

Related Papers

Abstract PO1-16-08: Real-World Outcomes of Patients Receiving First-line Palbociclib Plus Endocrine Therapy in Spain: Subgroup Analysis Based on Tumor Grade, Progesterone Receptor, Ki-67 and Histological Subtype from PALBOSPAIN Study

Cancer Research2024-05-021 citations

First-line therapy with palbociclib in patients with advanced HR<sup>+</sup>/HER2<sup>-</sup> breast cancer: The real-life study PALBOSPAIN.

2024-04-017 citations

Clinical outcomes and markers of treatment response in a randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-intact metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2020-05-207 citations

Cotargeting AR signaling and cell cycle: A randomized phase II study of androgen deprivation therapy with or without palbociclib in RB-positive metastatic hormone sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2018-02-205 citations

Feasibility of cotargeting cell cycle and androgen signaling in metastatic hormone-sensitive prostate cancer (mHSPC).

Journal of Clinical Oncology2017-02-20

Abstract IA06: Co-Targeting cell cycle and androgen signaling to personalize therapy for hormone dependent prostate cancer

Molecular Cancer Research2016-11-01

A randomized phase II study of androgen deprivation therapy with or without PD0332991 in RB-positive metastatic hormone-sensitive prostate cancer.

Journal of Clinical Oncology2015-05-201 citations